Imerys (NK) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
8 Jul, 2026Opening remarks and agenda
The meeting was chaired by Patrick Kron, with executive presentations from Alessandro Dazza and Sébastien Rouge, and included safety instructions, legal formalities, and confirmation of board and auditor presence.
The agenda covered 2024 results, Q1 2025 update, sustainability, dividend proposal, resolutions, auditor reports, Q&A, and voting.
The session was declared open, presentations were filmed and broadcast, and a Q&A session was scheduled for the end.
Financial performance review
2024 revenue reached EUR 3.605 billion, with 1% organic growth and adjusted EBITDA of EUR 675 million, up 10.4% like-for-like.
EBITDA margin improved to 18.7%, driven by operational leverage and higher joint venture contributions.
Net current income from continuing operations was EUR 262 million (+8.2%).
Free cash flow before strategic investments was EUR 66 million; net debt at year-end was EUR 1.275 billion, with net debt/EBITDA at 1.9x and investment grade ratings confirmed.
Q1 2025 revenue was EUR 871 million, up 0.7% like-for-like, with EBITDA at EUR 128 million and continued organic growth despite weak industrial markets.
Board and executive committee updates
Board composition changes included the renewal of Ian Gallienne and Lucile Ribot, and appointment of Nicolas Gheysens and Martin Doyen, maintaining 60% independence and 40% female representation.
Adjustments to 2025 compensation policies were made to enhance transparency and align with shareholder expectations.
Latest events from Imerys
- Solid organic growth, margin expansion, and strong ESG progress despite non-cash net loss.NK
H2 20249 Jul 2026 - All resolutions passed, with stable financials, new board members, and key strategic initiatives advanced.NK
AGM 20268 Jul 2026 - H1 2024 adjusted EBITDA rose 11% to €384 million, margin 20%, with strong net income growth.NK
H1 20248 Jul 2026 - Q1 2026 saw modest growth and margin gains, offset by FX and restructuring impacts.NK
Q1 202629 Apr 2026 - Stable 2025 results, major goodwill impairment, and cost savings plus lithium investment ahead.NK
Q4 202520 Feb 2026 - Nine-month EBITDA margin rose to 19.2% as full-year guidance is confirmed.NK
Q3 202417 Jan 2026 - Organic growth and sustainability progress offset margin pressure from joint venture declines.NK
Q1 202524 Dec 2025 - Stable H1 2025 sales and EBITDA, but net income fell; full-year EBITDA guidance reaffirmed.NK
Q2 202516 Nov 2025 - Revenue down 0.7% YTD; cost controls and strategic growth moves support profitability.NK
Q3 20251 Nov 2025